BFA
ENTA icon

BlackRock Fund Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

BlackRock Fund Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$48.5M Buy
1,447,002
+153,398
+12% +$4.4M 0.01% 1703
2016
Q3 		$34.4M Buy
1,293,604
+91,672
+8% +$2.13M 0.01% 1813
2016
Q2 		$26.5M Buy
1,201,932
+17,925
+2% +$469K 0.01% 1884
2016
Q1 		$34.8M Buy
1,184,007
+33,777
+3% +$940K 0.01% 1669
2015
Q4 		$38M Sell
1,150,230
-3,909
-0.3% -$127K 0.01% 1661
2015
Q3 		$41.7M Buy
1,154,139
+493,991
+75% +$21.2M 0.01% 1536
2015
Q2 		$29.7M Buy
660,148
+133,523
+25% +$5.19M 0.01% 1867
2015
Q1 		$16.1M Buy
526,625
+20,083
+4% +$781K ﹤0.01% 2182
2014
Q4 		$25.8M Buy
506,542
+257,293
+103% +$11.5M 0.01% 1909
2014
Q3 		$9.86M Sell
249,249
-5,457
-2% -$218K ﹤0.01% 2356
2014
Q2 		$11M Buy
254,706
+152,082
+148% +$5.8M ﹤0.01% 2363
2014
Q1 		$4.1M Buy
102,624
+2,844
+3% +$103K ﹤0.01% 2932
2013
Q4 		$2.72M Sell
99,780
-4,448
-4% -$108K ﹤0.01% 3094
2013
Q3 		$2.39M Buy
104,228
+12,384
+13% +$237K ﹤0.01% 3097
2013
Q2 		$1.63M Buy
+91,844
New +$1.79M ﹤0.01% 3124

Other funds holding ENTA

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Fund Advisors's ENTA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Enanta Pharmaceuticals (ENTA) stake by 12% in Q4 2016, buying an estimated $4.4M and bringing the position to 1,447,002 shares worth $48.5M. The position accounts for 0.01% of the portfolio, ranked #1703.

BlackRock Fund Advisors first reported a position in ENTA in Q2 2013 and has held it in 15 quarters since. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

  • BlackRock Fund Advisors held 1,447,002 shares of Enanta Pharmaceuticals worth $48.5M as of Q4 2016.
  • BlackRock Fund Advisors bought 153,398 Enanta Pharmaceuticals shares in Q4 2016, an estimated $4.4M.
  • Enanta Pharmaceuticals made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1703 holding.
  • BlackRock Fund Advisors first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • 149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.